Krystal Biotech Reports Positive Results for Skin Therapy

A pilot study of the KB113 therapy showed tumor regression in patients with Gorlin syndrome.

Updated on Oct. 15, 2026 in Biotech

Krystal Biotech Reports Positive Results for Skin Therapy

Live Poll

Should the government prioritize rapid development of genetic therapies for rare diseases despite health risks?

Krystal Biotech announced successful clinical results for its KB113 dermatology program, with three patients showing regression of basal cell carcinoma. Over 80% of assessed lesions regressed during the pilot study.

Why it matters

The therapy is designed to express interleukin-2 and interleukin-12 to stimulate immune-mediated tumor clearance. This breakthrough offers a potential new treatment pathway for patients with Gorlin syndrome.

Patients received six doses of up to 2 mL of 108 PFU/mL KB113 over a 14-week study period. Over half of all landmark lesions demonstrated greater than 50% clinical regression using an investigator-assessed 5-point clearance scale.

The players

Krystal Biotech

This Pittsburgh-based biotechnology company focuses on developing genetic medicines for skin and other diseases.

Dr. Shireen Guide

A lead investigator and medical expert, she is responsible for presenting the recent clinical findings at the PeDRA conference.

The details

The study confirmed complete histological clearance of injected lesions across all three adult participants, with secondary regression observed in non-injected sites. All reported adverse events were noted as transient and mild to moderate in severity.

The pilot study treatment duration spanned a 14-week period.
Dr. Shireen Guide presents the study results at the PeDRA conference from October 15-17, 2026.

Cancer
Oct. 6
FDA Approved Ameluz Gel for Skin Cancer Treatment
Diabetes
Sept. 30
Eli Lilly Drug Met Trial Endpoints for Dermatitis
Cancer
Oct. 14
Verastem Reported Positive Drug Trial Results

The Tech Race

This development moves beyond traditional surgical removal of basal cell carcinomas by utilizing gene therapy to drive localized expression of cytokines. It positions Krystal Biotech to compete in the growing market for genetic dermatological interventions.

For the estimated 10,000 Gorlin syndrome patients in the U.S., this treatment suggests a future alternative to invasive procedures. Patients should await further updates on clinical availability as the company coordinates with the FDA.

The takeaway

This pilot study demonstrates that gene-based therapies can effectively trigger immune responses to clear skin tumors. Patients with rare dermatological conditions should discuss these experimental developments with their specialists to understand potential future access.